# 2nd NovAliX Conference - Biophysics in Drug Discovery 2015

## Confirmed Speakers

### KEYNOTE LECTURE

#### Molecular Recognition in Protein-Ligand Complexes

Prof. Gerhard KLEBE
(PHILIPPS-UNIVERSITY MARBURG, Marburg, Germany)

### INVITED LECTURES

### SESSION 1: Method Development & Emerging Technologies

#### No Crystal, No Problem: Hydrogen Deuterium Exchange Mass Spectrometry in Drug Discovery

Dr Nino CAMPOBASSO
(GLAXOSMITHKLINE, Collegeville, United States)

#### Monitoring Drug Target Engagement in Cells and Tissues Using the Cellular Thermal Shift Assay

Dr Pär NORDLUND
(KAROLINSKA INSTITUTE & NANYANG TECHNOLOGICAL UNIVERSITY, Singapore, Singapore)

#### Second-Harmonic Generation (SHG) Measures and Resolves Protein Conformations: High-Throughput Structural Drug Discovery

Dr Joshua SALAFSKY
(BIODESY, South San Francisco, United States)

### SESSION 2: Biophysics for Integral Membrane Proteins

#### Fluorine NMR Screening: Principles and Application to a Membrane Protein

Dr Claudio DALVIT
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

#### Improving the Biophysical Properties of GPCRs for Drug Screening and Structural Biology

Prof. Andreas PLÜCKTHUN
(UNIVERSITY OF ZÜRICH, Zurich, Switzerland)

### SESSION 3: Impact of Biophysics on Drug Discovery Projects

#### Biophysical Approaches for Hit Finding and Evaluation at Bayer

Dr Ursula EGNER
(BAYER, Berlin, Germany)

#### Making Every Interaction Count: Impact of Biophysical Methods Across the AstraZeneca Small-Molecule Portfolio

# 2nd NovAliX Conference - Biophysics in Drug Discovery 2015

## Confirmed Speakers

Dr Stefan GESCHWINDNER
(ASTRAZENECA, Mölndal, Sweden)

**Some Examples of Biophysics Helping Drug Discovery**

Prof. Rod HUBBARD
(UNIVERSITY OF YORK & VERNALIS, Cambridge, United Kingdom)

**Biophysics and Structural Biology Enabling the Discovery of Therapeutic Solutions: from Small Molecule Inhibitors to Vaccine Design**

Dr Vincent MIKOL
(SANOFI, Vitry-sur-Seine, France)

### SESSION 4: The Use of Kinetics in Drug Discovery

**CCR2 Antagonists: From Structure-Kinetics Relatiosnhips to in vivo Efficacy**

Prof. Laura HEITMAN
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

**Towards a Better Understanding of the Structural Mechanisms of Kinase Inhibitor Binding Kinetics**

Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

**Analysis of Binding Kinetics and Thermodynamics of DPP-4 Inhibitors and their Relationship to Structure**

Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)

### SESSION 5: Special Focus on Epigenetics

**When to get Biophysical with Readers, Writers and Erasers**

Dr Chun-wa CHUNG
(GLAXOSMITHKLINE, Stevenage, United Kingdom)

**Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics**

Dr Robert A. COPELAND
(EPIZYME, Cambridge, United States)

**Interrogating the Bromodomain Family Through Chemical Biology**

# 2nd NovAliX Conference - Biophysics in Drug Discovery 2015

## Confirmed Speakers

Dr Richard CUMMINGS
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

### ORAL COMMUNICATIONS

#### Characterization of IL17A Inhibitors by Hydrogen/Deuterium Exchange Mass Spectrometry (HDX-MS)

Mr Alfonso ESPADA
(ELI LILLY, ALCOBENDAS, Spain)

#### A Universal Homogeneous Assay for High-Throughput Determination of Binding Kinetics

Dr Amaury FERNANDEZ MONTALVAN
(BAYER, Biberach an der Riss, Germany)

#### Drug Discovery at the Single Molecule Level

Dr Anders GUNNARSSON
(ASTRAZENECA, Mölndal, Sweden)

#### First Crystal Structure of Transmembrane Domain of G-Protein-Coupled Receptor MGLU5 Provides Insight Into Efficient New Drugs Design

Dr Krzysztof OKRASA
(HEPTARES THERAPEUTICS, Welwyn Garden City, United Kingdom)

#### CDK8 Inhibitors with Long Residence Time Emerging from a Retro-Design Approach: New Opportunities for Cancer Treatment

Dr Anita WEGERT
(MERCACHEM-SYNCOM, Nijmegen, The Netherlands)

#### Strategies to Target Protein-Protein Interactions

Dr Marta WESTWOOD
(UCB, Slough, United Kingdom)